Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Biopower Operations CorpFinancial_Report.xls
EX-32.1 - Biopower Operations Corpex32-1.htm
EX-31.1 - Biopower Operations Corpex31-1.htm

 

 

 

U. S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended February 28, 2015

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________________ to __________________

 

Commission File Number: 333-172139

 

 

BioPower Operations Corporation

(Exact name of registrant as specified in its charter)

 

Nevada   27-4460232
(State or other jurisdiction of   (IRS Employer
incorporation or organization)   Identification No.)

 

1000 Corporate Drive, Suite 200, Fort Lauderdale, Florida 33334

(Address of principal executive offices)

 

Issuer’s telephone number, including area code: (954) 202-6660

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ]   Accelerated filer [  ]
Non-accelerated filer [  ] (Do not check if a smaller reporting company)   Smaller reporting company [X]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.

 

As of May 13, 2015, the registrant had 41,607,680 shares of common stock, par value $0.0001 per share, outstanding.

 

 

 

 
 

 

BIOPOWER OPERATIONS CORPORATION

 

CONTENTS

 

      Page
PART I. FINANCIAL INFORMATION    
       
ITEM 1. FINANCIAL STATEMENTS   4
       
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   11
       
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK   16
       
ITEM 4. CONTROLS AND PROCEDURES   16
       
PART II. OTHER INFORMATION    
       
ITEM 1. LEGAL PROCEEDINGS   17
       
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS   17
       
ITEM 3. DEFAULT UPON SENIOR SECURITIES   17
       
ITEM 4. MINE SAFETY DISCLOSURES   17
       
ITEM 5. OTHER INFORMATION   17
       
ITEM 6. EXHIBITS   17
       
SIGNATURES   18
       
Exhibit 31.1 Certification Pursuant to Section 302 of the Sarbanes Oxley Act    
       
Exhibit 32.1 Certification Pursuant to Section 906 of the Sarbanes Oxley Act    

 

2
 

 

CONTENTS

 

    Page
     
Consolidated Balance Sheets as of February 28, 2015 (unaudited) and November 30, 2014   4
     
Consolidated Statements of Operations and Comprehensive Loss for the three months ended February 28, 2015 and 2014 (unaudited)   5
     
Consolidated Statements of Cash Flows for the three months ended February 28, 2015 and 2014 (unaudited)   6
     
Notes to Consolidated Financial Statements (unaudited)   7-10

 

3
 

 

PART IFINANCIAL INFORMATION

 

Item 1. Financial Statements

 

BioPower Operations Corporation and Subsidiaries

Consolidated Balance Sheets

 

   February 28, 2015   November 30, 2014 
   (Unaudited)     
         
Assets          
Current Assets          
Cash  $22,963   $15,118 
Prepaid expenses   204    818 
Total Current Assets   23,167    15,936 
           
Equipment - net   18,149    21,234 
Security deposit   11,193    11,193 
    29,342    32,427 
           
Total Assets  $52,509   $48,363 
           
Liabilities and Stockholders’ Deficit          
           
Current Liabilities          
Accounts payable and accrued expenses  $417,816   $419,090 
Accounts payable and accrued expenses - related parties   1,647,037    1,455,540 
Notes payable   217,500    155,000 
Notes payable - related parties   43,025    51,375 
Convertible debt, net of discount   3,333    62,500 
Convertible debt - related parties, net of discount   3,333      
Total Current Liabilities   2,332,044    2,143,505 
           
Total Liabilities   2,332,044    2,143,505 
           
Stockholders’ Deficit          
Preferred stock, $1 par value; 10,000 shares authorized; 1 share issued and outstanding   1    1 
Common stock, $0.0001 par value, 100,000,000 shares authorized; 41,607,676 and 41,107,676 shares issued and outstanding   4,162    4,112 
Additional paid-in capital   3,650,881    3,580,931 
Deficit accumulated   (5,934,579)   (5,680,186)
Total Stockholders’ Deficit   (2,279,535)   (2,095,142)
           
Total Liabilities and Stockholders’ Deficit  $52,509   $48,363 

 

See accompanying notes to unaudited consolidated financial statements

 

4
 

 


BioPower Operations Corporation and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss

Unaudited

 

   Three Months Ended 
   February 28,  
   2015   2014 
General and administrative expenses  $248,385   $360,453 
           
Other income (expense)          
Interest expense   (3,926)   (5,895)
Interest expense - related party   (2,082)   - 
Consulting revenue, net of expense   -    76,533 
Total other income (expense) - net   (6,008)   70,638 
           
Net loss  $(254,393)  $(289,815)
           
Net loss per common share - basic and diluted  $(0.01)  $(0.01)
          
Weighted average number of common shares outstanding during the period - basic and diluted   41,371,465    30,281,180 
           
Comprehensive loss          
Net loss  $(254,393)  $(289,815)
Unrealized loss on available-for-sale marketable securities   -    - 
Reclassification adjustment due to impairment on available-for-sale securities   -    - 
Comprehensive loss  $(254,393)  $(289,815)

 

See accompanying notes to unaudited consolidated financial statements

 

5
 

 

BioPower Operations Corporation and Subsidiaries

Consolidated Statements of Cash Flows

(Unaudited)

 

   Three Months Ended February,  
   2015   2014 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss   (254,393)  $(289,815)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation expense   -    103,750 
Depreciation   3,085    3,085 
Amortization of debt discount   1,667      
Changes in operating assets and liabilities:          
Accounts receivable   -    5,265 
Prepaid expenses   614    9,894 
Accounts payable and accrued expenses   (1,274)   (72,415)
Accounts payable and accrued expenses - related parties   191,496    114,953 
Net Cash Provided by (Used In) Operating Activities   (58,805)   (125,284)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of equipment   -    (4,754)
Net Cash Provided By (Used In) Investing Activities   -    (4,754)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from convertible debt   7,500    125,000 
Repayment notes payable - related parties   (850)   - 
Proceeds from issuance of common stock   60,000      
Net Cash Provided By Financing Activities   66,650    125,000 
           
Net Increase in Cash   7,845    (5,038)
           
Cash - Beginning of Period   15,118    109,172 
           
Cash - End of Period   22,963   $104,134 
           
SUPPLEMENTARY CASH FLOW INFORMATION:          
Cash Paid During the Period for:          
Income Taxes       $- 
Interest       $- 
           
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Common stock issued for conversion of notes payable  $-   $209,620 
Debt discount recorded on convertible debt  $5,000   $81,250 
Debt discount recorded on convertible debt - related party  $5,000   $- 
Reclassification-Jeffrey Kaliner   62,500      
Reclassification-Bonnie Nelson   7,500      

 

See accompanying notes to unaudited consolidated financial statements

 

6
 

 

BioPower Operations Corporation and Subsidiaries

Notes to Consolidated Financial Statements

February 28, 2015 and 2014

 

Note 1 Basis of Presentation

 

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is our opinion, however, that the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

 

In the quarter ending May 31, 2014, the Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the Company to remove the inception to date information and all references to development stage.

 

The accompanying unaudited interim consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended November 30, 2014 as filed with the SEC, which contains the audited financial statements and notes thereto, together with Management’s Discussion and Analysis, for the years ended November 30, 2014 and 2013. The financial information as of February 28, 2015 is derived from the audited financial statements presented in our Annual Report on Form 10-K for the year ended November 30, 2014. The interim results for the three months ended February 28, 2015 are not necessarily indicative of the results to be expected for the year ending November 30, 2015 or for any future interim periods.

 

Note 2 Going Concern

 

As reflected in the accompanying consolidated financial statements, the Company had a net loss of $254,393 and $289,815, for the three months ended February 28, 2015 and 2014, respectively, and net cash used in operations of $58,805 and $125,284 for the three months ended February 28, 2015 and 2014, respectively. Additionally, the Company had a working capital deficit of $2,308,877, for the three months ended February 28, 2015 and a stockholders’ deficit of $2,279,535 at February 28, 2015. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent on Management’s plans, which include potential asset acquisitions, mergers or business combinations with other entities, further implementation of its business plan and continuing to raise funds through debt and/or equity financings. The Company will likely rely upon related party debt and/or equity financing in order to ensure the continuing existence of the business.

 

7
 

 

BioPower Operations Corporation and Subsidiaries

Notes to Consolidated Financial Statements

February 28, 2015 and 2014

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Note 3 Equipment

 

At February 28, 2015 and November 30, 2014, equipment consists of the following:

 

   2015   2014   Estimated Useful Life
Computer Equipment  $27,760   $27,760   5 years
Testing Equipment   20,366    20,366   3 years
Less: Accumulated depreciation   (29,977)   (26,892)   
Equipment, net  $18,149   $21,234    

 

Depreciation expense was $3,085 and $3,085 for the three months ended February 28, 2015 and 2014, respectively.

 

Note 4 Notes Payable and Convertible Debt

 

Notes payable consists of the following:

 

    Balance     Interest Rate   Maturity
Balance – November 30, 2014  $155,000    8%  June 30, 2015
Reclassification of convertible debt to notes payable   62,500    8%  Due on Demand
Balance – February 28, 2015  $217,500         

 

In December, 2013, a third party investor purchased $125,000 of convertible debt, bearing interest, at 8% interest, and due February, 2015. In November, 2014, the Company converted $62,500 according to the terms of the Convertible Note Purchase Agreement. The remaining balance of $62,500 is not convertible to common shares of the Company’s stock. The $62,500 note payable bears interest at 8% and is due on May 25, 2015.

 

In December, 2014, a third party investor advanced $7,500, at 8% interest, which is due on December 30, 2015.

 

In December, 2014 a third party investor combined two previous loans dated July 2, 2013 and September 11, 2014 for $18,000 and $5,000, respectively, into a new loan of $23,000, at 8% interest. The new loan is payable on May 5, 2015.

 

Convertible debt consists of the following:

 

   Balance   Interest
Rate
   Maturity  Conversion
Price
 
                
Balance – November 30, 2014  $62,500    8%     $0.10 
Reclassification to notes payable   (62,500)             
Borrowings   7,500    8%  Dec. 30. 2015  $0.12 
Balance - February 28, 2015  $7,500    8%        

 

8
 

 

BioPower Operations Corporation and Subsidiaries

Notes to Consolidated Financial Statements

February 28, 2015 and 2014

 

On December 30, 2014 a third party investor advanced $7,500 due on or before December 30, 2015. Pursuant to the agreement, the investor is allowed to convert 100% of the debt at a share price of $0.12. The company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The loan was deemed to have a beneficial conversion feature because the fair value of the stock exceeded the effective conversion price embedded in the loan on the commitment date. Accordingly, the Company recorded the value of the beneficial conversion feature, which was determined to be $5,000 as a discount to the loan and a corresponding increase to additional paid in capital.

 

Accrued interest on notes payable and convertible debt at February 28, 2015 and February 28, 2014 amounted to $12,375 and $11,436, respectively, which is included as a component of accounts payable and accrued expenses.

 

Interest expense on notes payable and convertible debt with third parties amounted to $3,925 and $4,850 for the three months ended February 28, 2015 and 2014, respectively.

 

Note 5 Related Party Transactions

 

Notes payable to related parties at February 28, 2015 and November 30, 2014 is $43,025 and $51,375, respectively. Convertible notes payable to related parties is $7,500 at February 28, 2015.

 

Accrued interest at February 28, 2015 and November 30, 2014, amounted to $1,439 and $190, respectively and is a component of accounts payable and accrued expenses – related parties.

 

On November 5, 2014, the Director of Business Strategy made a loan of $50,000, bearing interest at 8% which is due on May 5, 2015. The $50,000 non-convertible loan included a provision for matching, future conversion rights with any new loans made by the company with the exception of a Right of First Refusal. On December 30, 2014, a third party investor loaned the Company $7,500 with conversion rights at $0.12 per share. Therefore, effective December 30, 2014, $7,500 of the director’s $50,000 note payable was reclassified to convertible debt with conversion rights of $0.12 per share. The company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The loan was deemed to have a beneficial conversion feature because the fair value of the stock exceeded the effective conversion price embedded in the loan on the commitment date. Accordingly, the Company recorded the value of the beneficial conversion feature, which was determined to be $5,000 as a discount to the loan and a corresponding increase to additional paid in capital.

 

The Company has separated accounts payable and accrued expenses on the balance sheet to reflect amounts due to related parties primarily consisting of officer compensation, health insurance, interest on notes and reimbursable expenses to officers for travel, meals and entertainment, vehicle and other related business expenses.

 

9
 

 

BioPower Operations Corporation and Subsidiaries

Notes to Consolidated Financial Statements

February 28, 2015 and 2014

 

Note 6 Stockholders’ Deficit

 

Common Stock

 

For the three months ended February 28, 2015:

 

The Company issued 500,000 shares of stock to unrelated third parties for cash totaling $60,000, at a price of $0.12 per share. There are 41,607,676 and 41,107,676 shares issued and outstanding at February 28, 2015 and November 30, 2014, respectively.

  

Note 7 Commitments and Contingencies

 

Commitments

 

Employment Agreements – Officers and Directors

 

As of November 30, 2014, the Company had employment agreements with certain officers and directors (two individuals) containing the following provisions:

 

Term of contract   4 years, expiring on November 30, 2018
Salary   $275,000 commencing December 1, 2014
Salary deferral   All salaries will be accrued but may be paid from the Company’s available cash flow funds.

 

Annual Salaries:

 

Name  Starting
Dec. 1, 2014
   2014-15    2015-2016    2016-2017  
Robert Kohn      $275,000   $325,000   $375,000 
                    
Bonnie Nelson      $275,000   $325,000   $375,000 

 

Lease Agreement

 

On June 3, 2013, the Company entered into a new lease agreement with its current landlord. The lease is for a 24 month period, expiring on May 31, 2015 , and requires monthly base rental payments of $ 4,000 for the period from June 1, 2013 through May 31, 2014 and $ 4,080 for the period from June 1, 2014 through May 31, 2015 plus adjustments for Common Area Expenses.

 

Rent expense was $12,821 and $16,606 for the three months ended February 28, 2015 and 2014, respectively.

 

Contingencies

 

From time to time, the Company may be involved in legal matters arising in the ordinary course of business. While the Company believes that such matters are currently not material, there can be no assurance that matters arising in the ordinary course of business for which the Company is, or could be, involved in litigation, will not have a material adverse effect on its business, financial condition or results of operations.

 

Note 8. Subsequent Events

 

None

 

10
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

FORWARD LOOKING STATEMENTS AND ASSOCIATED RISK

 

The information contained in this Quarterly Report on Form 10-Q (this “Quarterly Report”) is intended to update the information contained in our Annual Report on Form 10-K for the year ended November 30, 2014 (our “2014 Annual Report”) and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other information contained in our 2014 Annual Report. The following discussion and analysis also should be read together with our consolidated financial statements and the notes to the consolidated financial statements included elsewhere in this Quarterly Report.

 

This discussion summarizes the significant factors affecting the consolidated operating results, financial condition and liquidity and cash flows of BioPower Operations Corp. for the three months ended February 28, 2015 and 2014. Except for historical information, the matters discussed in this Management’s Discussion and Analysis of Financial Condition and Results of Operations are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements involve risks and uncertainties and are based upon judgments concerning various factors that are beyond our control. Forward-looking statements are based on current expectations and assumptions and actual results could differ materially from those projected in the forward-looking statements as a result of, among other things, those factors set forth in “Risk Factors” contained in Item 1A of our 2014 Annual Report.

 

Throughout this Quarterly Report, the terms “we,” “us” and “our” refers to BioPower Operations Corporation and, Unless the context otherwise requires, The “Company”, “we,” “us,” and “our,” refer to (i) BioPower Operations Corporation.; (ii) BioPower Corporation (“BC”), Green3Power Holdings Company and its subsidiaries (“G3P”), Green Oil Plantations Americas Inc. (“Green Oil”), Green Energy Crops Corporation (“GECC”), Agribopo, Inc., FTZ Exchange LLC and FTZ Energy Corporation. Unless otherwise indicated, all monetary amounts are reflected in United States Dollars.

 

Overview

 

From inception (September 13, 2010) to November 30, 2014, the Company focused on growing biomass crops coupled with the project development of processing and/or conversion facilities to produce oils, biofuels, electricity and other biomass products. We also intended to utilize licensed patented technology to convert biomass wastes into products and reduce the amount of waste going to landfills.

 

Today, BioPower and its subsidiaries intend to focus on developing waste to energy projects globally by designing, engineering, permitting, procuring equipment, construction management and operating and maintaining facilities for the conversion of wastes into electricity and synthetic fuels through licensed gasification technology. The Company intends to also provide waste remediation services.

 

Our corporate headquarters are located at 1000 Corporate Drive, Suite 200, Fort Lauderdale, Florida 33334 and our phone number is (954) 202-6660. Our website can be found at www.biopowercorp.com. The information on our website is not incorporated in this report.

 

11
 

  

Our Business

 

Typical Gasification Electricity or Synthetic Fuel Production Facility

 

G3P designs, permits, procures equipment, manages construction, intends to partially own and intends to operate and maintain Gasification Waste-to-Energy power plants, using our unique licensed thermal licensed gasification technology, an upgrade to present licensed gasification technology in use around the world for the last 30 years. These innovative gasifier designs enable the company to enhance the thermal output which could provide an increase in revenues and bottom lines. We intend to produce energy through the gasification of non-hazardous municipal solid waste (“MSW”) or other wastes including used tires, tree cuttings, construction and demolition (C&D) wastes and biomass in our specially designed refuse-derived fuel facilities which process waste prior to combustion and gasification, in which waste is heated to create gases (syngas) which are then combusted into steam which can be turned into electricity through traditional steam turbines or create fuel through a Fisher-Tropsch process that has been used for almost the last one hundred years to create fuels. There can be no assurance we will ever build our first WtE facility.

 

To our knowledge this is the cleanest and most cost effective technology for the conversion of wastes to produce electricity or synthetic fuels. Utilizing a Sorting Facility and an advanced dryer system on the front-end, enables solid wastes, construction & demolition wastes, medical, biological, and pharmaceutical wastes, and used tires as feedstock to produce electricity and synthetic fuels. The front-end drying system is especially helpful in developing countries where there is high organic content and high moisture content waste. G3P also intends to provide waste remediation services.

 

On November 13, 2013 we entered into a joint venture agreement and formed MicrobeSynergy, LLC, a 50-50 joint venture for the exclusive distribution of a cellulosic advanced biofuels technology. We have to meet certain Milestones to maintain exclusivity otherwise we would have a non-exclusive license. The Company believes that we met Milestone I but we have received notification from our joint venture partner that we did not meet Milestone 1. As part of our October 24, 2014 transaction below, we have agreed to sell our interest in this joint venture.

 

On October 24, 2014, BioPower Operations Corporation (the “Company” or “BOPO”) executed a Share Exchange Agreement (“SEA”) with Green3Power Holdings Company (“G3P”) to acquire G3P and its wholly-owned subsidiaries Green3Power Operations Inc., a Delaware corporation (“G3P OPS”) and Green3Power International Company, a Nevis Corporation (“G3PI”). Pursuant to the terms thereof, at Closing (as defined in the Share Exchange Agreement), and following the Closing, G3P, G3P OPS and G3PI will be wholly-owned subsidiaries of the Company. G3P is an engineering firm developing waste-to-energy projects using licensed gasification technology, which can convert wastes to energy including electricity, diesel fuels and advanced biofuels. G3P designs, procures, constructs, intends to partially own, operate and maintain Gasification Waste-to-Energy power plants, using their unique thermal licensed gasification technology, an upgrade to present licensed gasification technology in use around the world for the last 30 years. G3P also provides waste remediation services.

 

We have not yet generated or realized any revenues from business operations. Our auditors have issued a going concern opinion. This means there is substantial doubt that we can continue as an on-going business for the next twelve (12) months unless we obtain additional capital to pay our bills. This is because we have not generated any revenues and no revenues are anticipated until we begin marketing our products to customers. Accordingly, we must raise cash from sources other than revenues generated such as from the proceeds of loans, sale of common shares and advances from related parties.

 

12
 

  

Licensed Technologies

 

Green3Power Holdings Company – Licensed gasification technology for Waste-to-Energy Conversion

 

G3P has an exclusive global License for the use of the technologies and processes for building gasification facilities to convert wastes into electricity and synthetic fuels. Once the royalties paid for the use of these technologies equal $10,000,000, G3P will then own 100% of the technologies and processes without any further license fees. The initial license fees are paid based upon gross revenues of the facilities and their waste conversion operations using the gasification technologies and processes.

 

Enzyme Technology

 

We have a non-exclusive global License for a patented one-step enzyme technology which converts wastes from poultry, hogs, humans and sugar to products such as fertilizer, cellulosic ethanol and other products. The patent expires in June 2029. Under the terms of the agreement, we pay our Licensor 50% of any sub-license fees that we receive. We also pay our Licensor 12% of all royalties on all revenues we earn from utilizing the technology. This 12% is calculated on the basis of net gross revenues which equal gross revenues less all direct costs associated with the production of the revenues. As part of our October 24, 2014 transaction above, we have agreed to sell our interest in this license.

 

Critical Accounting Policies

 

In response to financial reporting release FR-60, Cautionary Advice Regarding Disclosure About Critical Accounting Policies, from the SEC, we have selected our more subjective accounting estimation processes for purposes of explaining the methodology used in calculating the estimate, in addition to the inherent uncertainties pertaining to the estimate and the possible effects on the our financial condition. The accounting estimates involve certain assumptions that, if incorrect, could have a material adverse impact on our results of operations and financial condition. Our more significant accounting policies can be found in Note 3 of our unaudited interim consolidated financial statements found elsewhere in this report and in our Annual Report on Form 10-K for the year ended November 30, 2014, as filed with the SEC. There have been no material changes to our critical accounting policies during the period covered by this report.

 

Results of Operations

 

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. We expect that we will require additional capital to meet our operating requirements. We expect to raise additional capital through, among other things, the sale of equity and/or debt securities.

   

Three Months Ended February, 2015 Compared to the Three Months Ended February 28, 2014

 

The following tables set forth, for the periods indicated, results of operations information from our unaudited interim consolidated financial statements:

 

   Three Months Ended
February 28,
   Change    Change  
   2015    2014    (Dollars)    (Percentage)  
                 
Expenses                     
General and administrative expenses  $248,385   $360,453   $(112,068)   -31. 09 % 
                     
Other Income (Expense)                     
Interest expense   3,926    5,895    (1,969)   -33.49%
Interest expense - related party   2,082    -    2,082    100.0%
    -    -           
Consulting revenue, net   -    76,533    (76,533)   -100.0%
                     
Total Other Income - net    (6,008)   70,638    (76,646)   (108.5)%
                     
Net loss   $(254,393)  $(289,815)  $(35,422)   (12.2)%

 

13
 

  

General and Administrative Expenses. Our general and administrative expenses are mainly comprised of compensation expense, corporate overhead, development costs, and financial and administrative contracted services for professional services including legal and accounting, SEC filing fees, and insurance. The decrease in our general and administrative expenses is primarily attributable to lower compensation expense because there were no outside consultants in the three months ended February 28, 2015, and there was no stock based compensation for the period ending February 28, 2105.

 

Interest Expense. Interest expense for the three months ended February 28, 2015 and 2014 primarily represents the accretion of debt discount to interest expense on our outstanding debt, as well as contractual interest expense on our notes payable and convertible debt.

 

Consulting Revenue. During the three months ended February 28, 2015 and 2014, the Company recognized $0 and $76,533, respectively; in net consulting revenue related to the consulting agreement entered into with a third party in February 2013. The consulting agreement was terminated during the year ended November 30, 2014.

 

14
 

 

Liquidity and Financial Condition

 

   Three Months Ended February 28, 
Category  2015   2014 
         
Net cash used in operating activities  $(58,805)  $(125,284)
Net cash provided by financing activities   66,650    125,000 
           
Net increase (decrease) in cash  $7,845   $(5,038)

 

Cash Flows from Operating Activities

 

Net cash used in operating activities was $58,805 for the three months ended February 28, 2015, compared with 125,284 for the comparable period in 2014. Net cash used in operating activities for the three months ended February 28, 2015 is mainly attributable to our net loss of $254,393, offset by an increase in accounts payable and accrued expenses. Net cash used in operating activities for the three months ended February 28, 2014 is mainly attributable to our net loss of $289,815, offset by the loss on impairment of securities, an increase in accounts payable and accrued expenses due to related parties and an increase inconvertible debt and notes payable

 

Cash Flows from Financing Activities

 

We have financed our operations primarily from either advancements or the issuance of equity and debt instruments. For the three months ended February 28, 2015 cash flows provided by financing activities was $66,650, compared to $125,000 for the comparable period in 2014. We received $7,500 in proceeds from convertible debt and notes payable with third parties and related parties during the three months ended February 28, 2015, compared to $125,000 in proceeds from convertible debt during the three months ended February 28, 2014. Management is seeking, and expects to continue to seek to raise additional capital through equity and/or debt financings, including through one or more equity or debt financings to fund its operations, and pay amounts due to its creditors and employees. However, there can be no assurance that the Company will be able to raise such additional equity or debt financing or obtain such bank borrowings on terms satisfactory to the Company or at all.

 

The Company does not currently have sufficient resources to cover on-going expenses and expansion. As of February 28, 2015, the Company had cash of $22,963 and current liabilities of $2,332,044. Our current liabilities include accounts payable and accrued expenses to related parties of $1,647,037. We have historically financed our operations primarily through private placements of common stock, loans from third parties and loans from our Officer. We plan on raising additional funds from investors to implement our business model. In the event we are unsuccessful, this will have a negative impact on our operations.

 

As reflected in the accompanying unaudited interim consolidated financial statements, the Company has a net loss of $254,393 and net cash used in operations of $58,805 for the three months ended February 28, 2015; and a working capital deficit of $2,308,877 at February 28, 2015. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent on Management’s plans, which include potential asset acquisitions, mergers or business combinations with other entities, further implementation of its business plan and continuing to raise funds through debt and/or equity financings. The Company will likely rely upon related party debt and/or equity financing in order to ensure the continuing existence of the business. The financial statements have been prepared assuming that we will continue as a going concern, which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business.

 

Recent Accounting Pronouncements

 

See Note 3 to our unaudited interim consolidated financial statements regarding recent accounting pronouncements.

 

Off-Balance Sheet Arrangements

 

As of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

15
 

  

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

This item is not applicable to smaller reporting companies.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of February 28, 2015, the end of the period covered by this report. Based on, and as of the date of such evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of February 28, 2015 such that the information required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Changes in Internal Control Over Financial Reporting

 

There have not been any significant changes in our internal control over financial reporting during the fiscal quarter ended February 28, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

16
 

  

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

From time to time, we are a party to, or otherwise involved in, legal proceedings arising in the normal and ordinary course of business. As of the date of this report, we are not aware of any proceeding, threatened or pending, against us which, if determined adversely, would have a material effect on our business, results of operations, cash flows or financial position.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

ITEM 6. EXHIBITS.

 

The following exhibits are being filed as part of this Quarterly Report on Form 10-Q.

 

Exhibit    
Number   Exhibit Description
     
31.1   Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d- 14(a)
     
32.1   Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d- 14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

Copies of this report (including the financial statements) and any of the exhibits referred to above will be furnished at no cost to our shareholders who make a written request to BioPower Operations Corp., 1000 Corporate Drive, Suite 200, Fort Lauderdale, Florida 33334 Attention: Mr. Robert Kohn.

 

17
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: May 13, 2015 BioPower Operations Corporation
   
  By: /s/ Robert D. Kohn
    Robert D. Kohn, Chairman and Chief Executive
    Officer and Chief Financial Officer

 

18